U.S. markets closed

BioSig Technologies, Inc. (BSGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5600-0.0600 (-2.29%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.6200
Bid2.5000 x 1100
Ask2.6500 x 1400
Day's Range2.4703 - 2.7000
52 Week Range2.3500 - 6.1400
Avg. Volume151,000
Market Cap89.405M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateNov 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BSGM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioSig Technologies, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Benzinga

    Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This Stock

    BioSig Technologies, Inc. (NASDAQ: BSGM) announced that an article titled "Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study" has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access as of September 23, 2021, via the Wiley Online Library. The PURE EP 2.0 study was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic

  • GlobeNewswire

    BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias

    Company’s signal processing technology for arrhythmia care to be featured during the event co-hosted by the University of Pennsylvania and The Mount Sinai HospitalWestport, CT, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its flagship te

  • Benzinga

    BioSig Inks Manufacturing Deal with Plexus Corp

    Photo by Anna Shvets from Pexels With the recent successes of its PURE EP™ system underway, BioSig Technologies Inc. (NASDAQ: BSGM) has continued its trend of growth and innovation. Thanks to a manufacturing and professional services agreement with Plexus Corp. (NASDAQ: PLXS), a global leader in complex product design, PURE EP will be brought to market in one of the company’s largest market sectors: healthcare and life sciences. Ultimately, these two industries bring an enormous amount of revenu